TENELIGOLD PM 500 MedlinePlus Drug Information.....

TENELIGOLD PM 500

Pioglitazone (15mg) and Extended Release Metformin Hydrochloride (500mg) TENELIGOLD PM 500

TENELIGOLD PM 500 combines Pioglitazone (15mg) and Extended Release Metformin Hydrochloride (500mg) to offer an effective solution for managing Type 2 Diabetes Mellitus (T2DM). This dual-action medication leverages the complementary mechanisms of both drugs to improve glycemic control, enhance insulin sensitivity, and promote better overall diabetes management. Ideal for patients requiring comprehensive diabetes care, TENELIGOLD PM 500 simplifies the treatment regimen while maximizing efficacy.

Composition

Pioglitazone (15mg): A thiazolidinedione that enhances insulin sensitivity.
Extended Release Metformin Hydrochloride (500mg): A biguanide that decreases hepatic glucose production and improves insulin sensitivity.

Mechanism of Action

Pioglitazone

Pioglitazone works by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ) in the adipose tissue, muscle, and liver. This activation improves the body's sensitivity to insulin, enhancing glucose uptake and utilization by the cells, and reducing hepatic glucose output.

Extended Release Metformin Hydrochloride

Metformin Hydrochloride (Sustained Release) primarily inhibits hepatic gluconeogenesis, reducing the amount of glucose produced by the liver. Additionally, it enhances insulin sensitivity in peripheral tissues, promoting better glucose uptake by muscles and fat cells. The extended-release formulation ensures a gradual release of the medication, minimizing gastrointestinal side effects and improving patient compliance.

Indications

TENELIGOLD PM 500 is indicated for the treatment of Type 2 Diabetes Mellitus in adults. It is particularly beneficial for patients who:

• Have not achieved adequate glycemic control with diet and exercise alone.
• Require combination therapy to maintain optimal blood sugar levels.
• Are transitioning from monotherapy to a more effective dual therapy.

Dosage and Administration

Initial Dose

• One tablet of TENELIGOLD PM 500 (Pioglitazone 15mg, Extended Release Metformin Hydrochloride 500mg) taken once daily, preferably with a meal to enhance absorption and reduce gastrointestinal side effects.

Maintenance Dose

• The dosage may be adjusted based on the patient's response and tolerance. Regular monitoring of blood glucose levels is essential to tailor the treatment to individual needs.

Benefits of TENELIGOLD PM 500

1. Enhanced Glycemic Control: The combination of Pioglitazone and Metformin SR provides a synergistic effect, leading to better management of blood sugar levels.
2. Improved Insulin Sensitivity: Pioglitazone enhances the body's response to insulin, improving glucose uptake and utilization.
3. Weight Management: Pioglitazone may help in reducing visceral fat, while Metformin is weight-neutral or may promote slight weight loss.
4. Reduced Risk of Hypoglycemia: The glucose-dependent action of Pioglitazone and the weight-neutral effect of Metformin minimize the risk of hypoglycemia.
5. Improved Compliance: Combining two effective medications into a single tablet simplifies the treatment regimen.

Potential Side Effects

Common Side Effects

• Pioglitazone: Weight gain, edema, upper respiratory tract infection.
• Metformin SR: Gastrointestinal issues such as diarrhea, nausea, vomiting, and abdominal discomfort.

Serious Side Effects

• Heart Failure: Pioglitazone may cause or exacerbate congestive heart failure in some patients. Monitor for signs of heart failure, including rapid weight gain, dyspnea, and edema.
• Lactic Acidosis: A rare but serious side effect of Metformin characterized by muscle pain, difficulty breathing, abdominal pain, and fatigue. Patients with renal impairment or conditions predisposing them to hypoxia are at higher risk.
• Bladder Cancer: Long-term use of Pioglitazone has been associated with an increased risk of bladder cancer. Monitor for symptoms such as blood in the urine, urinary urgency, and pain during urination.

Precautions and Warnings

1. Renal Impairment: Regular monitoring of renal function is necessary, as Metformin is contraindicated in severe renal impairment.
2. Hepatic Impairment: Use with caution in patients with liver disease.
3. Heart Failure: Pioglitazone should be used cautiously in patients with a history of heart failure.
4. Pregnancy and Lactation: Consult a healthcare provider, as the safety of this combination in pregnant or breastfeeding women is not well established.
5. Bladder Cancer: Patients with a history of bladder cancer should use Pioglitazone with caution.

Drug Interactions

• Diuretics: Enhanced diuretic effect can increase the risk of dehydration and hypotension.
• Insulin and Insulin Secretagogues: Combination with these agents can increase the risk of hypoglycemia.
• Cimetidine: May increase the effects of Metformin by reducing its renal clearance.
• Rifampicin: May reduce the efficacy of Pioglitazone by increasing its metabolism.

Monitoring Parameters

1. Blood Glucose Levels: Regular self-monitoring to ensure adequate glycemic control.
2. HbA1c Levels: Periodic testing to assess long-term glycemic control.
3. Renal Function: Regular monitoring, especially in patients with pre-existing renal conditions.
4. Liver Function Tests: Periodic testing to ensure hepatic safety.
5. Signs of Heart Failure: Monitor for symptoms such as rapid weight gain, dyspnea, and edema.

Conclusion

TENELIGOLD PM 500, combining Pioglitazone (15mg) and Extended Release Metformin Hydrochloride (500mg), offers a comprehensive solution for managing Type 2 Diabetes Mellitus. This medication not only improves glycemic control but also enhances insulin sensitivity and provides additional benefits such as weight management and improved patient compliance. As always, it is essential to consult a healthcare provider to determine if TENELIGOLD PM 500 is the right choice for your diabetes management plan. Regular monitoring and adherence to prescribed dosages will help maximize the therapeutic benefits while minimizing potential risks.Steris Healthcare Pvt Ltd, established in February 2018 by seasoned professionals in the pharmaceutical sector, operates under the name Sterispharma. Headquartered in Navi Mumbai, the company is certified by WHO, GMP, and ISO. Sterispharma is dedicated to providing high-quality medications at affordable prices across India, adhering to stringent WHO guidelines. They offer an online pharmacy platform for easy medicine purchases and home delivery. The company's mission is to deliver a diverse range of healthcare products catering to the varied needs of the medical community. From advanced treatments and rare condition medications to essential health supplies, Sterispharma aims to meet the extensive demands of the healthcare industry. Their product range covers numerous health fields, including Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

For further information: 

EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

CALL/WHATSAPP: 7877551268, 7849827488

BUY NOW